ICAP Quarterly Master Slide Set July-September 2007
description
Transcript of ICAP Quarterly Master Slide Set July-September 2007
ICAP Quarterly Master Slide SetJuly-September 2007
Site Census
• What: Ongoing, real-time inventory of all planned, current, and closed ICAP sites. Supported activities, funding source(s) and their targets are also captured
• Purpose: To have one up to date master list of sites, activities, funding sources, and targets that all ICAP staff can refer to for planning and evaluation
240214
10492
237
170196
243
409
0
200
400
Overa
ll
Care
& trea
tmen
t
TB scr
eenin
g fo
r HIV
pts
HIV te
sting
for T
B pts
PMTCT
PM
TCT+EID
PICT/
VCTLa
b
Source: ICAP Site Census, November 2007
Number of ICAP-supported sites by activity, September 2007 (n=409)
Nu
mb
er
of
site
s
Source: ICAP Site Census, November 2007
Number of ICAP-supported sites by country, September 2007 (n=409)
Nu
mb
er
of
site
s
Programmatic components funded at ICAP-supported care and treatment sites (n=243),
September 2007
37%43%
49%
60%65%
81%
100%
0%
50%
100%
Care &Treatment
TBscreening inHIV patients
Lab HIV testingin TB
patients
PICT/VCT PMTCT Early infantdiagnosis
Type of activity
Source: ICAP Site Census, November 2007
% c
are
and
trea
tmen
t si
tes
with
act
ivity
Program and Facility Characteristics Tracking System (PFaCTS)
• What: Collects program and facility information on ICAP-supported care and treatment programs semi-annually
• Purpose: To describe the scope, diversity, and comprehensiveness of ICAP-supported care and treatment programs, and evaluate multi-level factors that influence program performance and patient-level outcomes
0%
50%
100%
Urban Rural
Primary Secondary Tertiary
Location and type of ICAP-supported HIV care and treatment sites (n=177)
Source: PFaCTS, January 2007
120 57
% s
ites
On-site HIV service infrastructure at ICAP-supported HIV care and treatment sites by type of
service (n=177)
Source: PFaCTS, January 2007
% s
ites
with
ser
vice
Number of on-site HIV service infrastructure* provided at ICAP-supported HIV care and
treatment sites (n=177)
Source: PFaCTS, January 2007
*Services include: VCT, TB treatment, PMTCT, Labor and delivery, and ART pharmacy.
On-site HIV service infrastructure* at ICAP-supported HIV care and treatment sites by country
(n=177)
Source: PFaCTS, January 2007
49%
75%82%
87%94%97%99%100%100%
0%
50%
100%
Swazila
nd
Leso
tho
Niger
ia
Ethiop
ia
Tanza
nia
Kenya
Rwanda
Moz
ambiq
ue
South
Afri
ca
* Sites that have >=4 of the following on-site services are represented in the graph: VCT, TB treatment, PMTCT, Labor and delivery and ART pharmacy.
ICAP Average
=80%
% s
ites
with
ser
vice
Type of patient support services available at ICAP-supported HIV care and treatment sites (n=177)
Source: PFaCTS, January 2007
* Only counts those sites that provide adherence support by trained personnel. Other categories of adherence support activities are not represented here.
% s
ites
with
ser
vice
Number of patient support services provided at ICAP-supported HIV care and treatment sites (n=177)
Source: PFaCTS, January 2007
* Services include: ART adherence support, outreach program, peer educator program, food support for adults, food support for infants.
0% 0% 0% 0%
6%9%
21%
33%
68%
0%
50%
100%
Comprehensiveness* of on-site patient support services at ICAP-supported HIV care and treatment
sites (n=177)
Source: PFaCTS, January 2007
* Comprehensiveness is defined as availability of >=4 of the following on-site patient-support services: ART adherence support, outreach program, peer educator program, food support for infants, and food support for adults.
ICAP Average
=20%
% o
f si
tes
with
ser
vice
Laboratory test availability at ICAP-supported HIV care and treatment sites (n=177)
Source: PFaCTS, January 2007
% s
ites
with
labo
rato
ry t
est
s
Number of laboratory test services* available through ICAP-supported HIV care and treatment sites (n=177)
Source: PFaCTS, January 2007
* Services include: CD4, CD4 percent, HIV-RNA, early infant diagnosis, LFT, and blood chemistry. ** No sites had access to all 6 laboratory test services.
47%
66%
83%86%87%90%96%97%100%
0%
50%
100%
Source: PFaCTS, January 2007
Availability of core HIV-related laboratory tests through ICAP-supported HIV care and treatment sites (n=177)
* Comprehensiveness is defined as availability of >=4 of the following laboratory test services: Services include: CD4, CD4 percent, HIV-RNA, LFT, and blood chemistry. PCR laboratory tests are excluded.
ICAP Average
=86%
% s
ites
with
labo
rato
ry t
est
s
0% 0%
12%24%
30%
67%
83%90%92%
0%
50%
100%
Source: PFaCTS, January 2007
Availability of PCR laboratory tests through ICAP-supported HIV care and treatment sites (n=177)
ICAP Average
=58%
% s
ites
with
PC
R t
ests
0
50
100
Overa
ll
Nigeria
Rwanda
South
Africa
Ethiopia
Tanzan
ia
Moza
mbiq
ue
Kenya
Leso
tho
Physicians Health officers/medical assistants Nurses
Mean number of health care providers per 1000 patients on ART at ICAP-supported HIV care and
treatment sites (n=177)
Source: PFaCTS, January 2007
Num
ber
of
hea
lth c
are
pro
vid
ers
per/
100
0 pa
tient
s on
AR
T
Mean number of outreach workers per 1000 patients on ART at ICAP-supported HIV care and
treatment sites (n=79)*
Source: P-FaCTS, January 2007
*For sites with outreach programs
ICAP Average
=15.1
HIV care and treatment services
0
200,000
400,000
Jul 04 Oct 04 Jan 05 Apr 05 Jul 05 Oct 05 Jan 06 Apr 06 Jul 06 Oct 06 Jan 07 Apr 07 Jul 07
Nu
mb
er
of
pa
tie
nts
0
100
200
Nu
mb
er
of
fac
iliti
es
HIV care ART Facilities reporting
Kenya, Lesotho, Rwanda, S. Africa, Tanzania
Mozambique
Ethiopia
Nigeria, Swaziland,
Zambia
Cumulative enrollment at ICAP-supported HIV care and treatment programs (ever-supported),
July 2004 - September 2007*
Source: ICAP URS, November 2007
326,859
150,562
*Includes all transitioned sites with data carried over.
0
20,000
40,000
Jul 04 Oct 04 Jan 05 Apr 05 Jul 05 Oct 05 Jan 06 Apr 06 Jul 06 Oct 06 Jan 07 Apr 07 Jul 07
Nu
mb
er
of
pa
tie
nts
0
100
200
Nu
mb
er
of
fac
iliti
es
HIV care ART Facilities reporting
Mozambique
Ethiopia
Cumulative pediatric enrollment in ICAP-supported HIV care and treatment programs (ever-supported),
July 2004 - September 2007*34,216
13,438
*Includes all transitioned sites with data carried over.
Kenya, Lesotho, Rwanda, S. Africa, Tanzania
Nigeria, Swaziland,
Zambia
Source: ICAP URS, November 2007
0
200,000
400,000
Jul 04 Oct 04 Jan 05 Apr 05 Jul 05 Oct 05 Jan 06 Apr 06 Jul 06 Oct 06 Jan 07 Apr 07 Jul 07
Nu
mb
er o
f p
atie
nts
0
100
200
Nu
mb
er o
f fa
cilit
ies
HIV care ART Facilities reporting
Kenya, Lesotho, Rwanda, S. Africa, Tanzania
Mozambique
Ethiopia
Nigeria, Swaziland,
Zambia
Cumulative enrollment in ICAP-supported HIV care and treatment programs (currently supported),
July 2004 - September 2007*300,743
136,252
*Excludes all transitioned sites.
Source: ICAP URS, November 2007
0
15,000
30,000
Jul 04 Oct 04 Jan 05 Apr 05 Jul 05 Oct 05 Jan 06 Apr 06 Jul 06 Oct 06 Jan 07 Apr 07 Jul 07
Nu
mb
er
of
pa
tie
nts
0
100
200
Nu
mb
er
of
fac
iliti
es
HIV care ART Facilities reporting
Kenya,
Rwanda, S. Africa, Tanzania
Mozambique
Ethiopia
Nigeria
Cumulative pediatric enrollment in ICAP-supported HIV care and treatment programs (currently supported),
July 2004 - September 200730,670
12,253
Source: ICAP URS, November 2007
*Excludes all transitioned sites.
Current, projected, and target cumulative enrollment in ICAP-supported care and treatment programs by
ART status*
262,173
114,689
311,206
137,520
257,604
106,794
0
100,000
200,000
300,000
HIV care ART
Current enrollment, Sept 07Projected enrollment, Feb 08Target enrollment, Feb 08
Source: ICAP URS, November 2007
Num
ber
of p
atie
nts
* Targets were available for MCAP countries, including Ethiopia, Kenya, Mozambique, Nigeria, Rwanda, South Africa and Tanzania.
Current, projected and target cumulative HIV care enrollment in ICAP-supported care and treatment
programs by country
0
50,000
100,000
Ethiopia Kenya Mozambique Nigeria Rwanda South Africa Tanzania
Current enrollment, Sept 07Projected enrollment, Feb 08Target enrollment, Feb 08
Source: ICAP URS, November 2007
Num
ber
of p
atie
nts
Current, projected and target cumulative ART enrollment in ICAP-supported care and treatment
programs by country
0
20,000
40,000
Ethiopia Kenya Mozambique Nigeria Rwanda South Africa Tanzania
Current enrollment, Sept 07Projected enrollment, Feb 08Target enrollment, Feb 08
Source: ICAP URS, November 2007
Num
ber
of p
atie
nts
0
50,000
100,000
150,000
Cumulative and current enrollment in ART care at ICAP-supported HIV care and treatment programs,
July 2004 - September 2007
Cumulative initiating ART
ART patients retained in care
Source: ICAP URS, November 2007
Lost to follow up
Dead*
Num
ber
of p
atie
nts
* Includes known deaths only.
Mozambique
Ethiopia
South Africa
RwandaLesotho
KenyaTanzania
NigeriaSwaziland
Zambia
0
100,000
200,000
300,000
Jul
04
Oct
04
Jan
05
Apr 0
5
Jul
05
Oct
05
Jan
06
Apr 0
6
Jul
06
Oct
06
Jan
07
Apr 0
7
Jul
07
Cumulative enrollment in HIV care in ICAP-supported HIV care and treatment programs by country,
July 2004 - September 2007 (n=300,743)
Num
ber
of p
atie
nts
Cumulative enrollment on ART at ICAP-supported HIV care and treatment programs by country, July 2004 - September 2007 (n=136,252)
Source: ICAP URS, November 2007
Mozambique
South Africa
Ethiopia
Rwanda
Swaziland
TanzaniaKenya
Lesotho
NigeriaZambia
0
50,000
100,000
150,000
Jul
04
Oct
04
Jan
05
Apr 0
5
Jul
05
Oct
05
Jan
06
Apr 0
6
Jul
06
Oct
06
Jan
07
Apr 0
7
Jul
07
Num
ber
of p
atie
nts
Cumulative enrollment in ICAP-supported HIV care and treatment programs by ART status, age, and sex,
July 2004 – September 2007Total care enrollment (n=300,743) Total ART enrollment (n=136,252)
Source: ICAP URS, November 2007
0
100,000
200,000
300,000
Jul04
Oct04
Jan05
Apr05
Jul05
Oct05
Jan06
Apr06
Jul06
Oct06
Jan07
Apr07
Jul07
0
100,000
200,000
300,000
Jul04
Oct04
Jan05
Apr05
Jul05
Oct05
Jan06
Apr06
Jul06
Oct06
Jan07
Apr07
Jul07
Children <15
Men 15+
Women 15+
Children <15
Men 15+
Women 15+
Proportion of patients ever enrolled in HIV care who initiated ART in ICAP-supported care and treatment
programs by country as of September 2007*
31%35%
40%42%
44%48%49%
56%57%
43%
0%
25%
50%
n=40, 575 n=19,869n=29,169 n=13,098 n= 96,816n=21,743 n=288,818 n=40,903
Source: ICAP URS, November 2007
% p
atie
nts
initi
atin
g A
RT
n=4,635 n=22,010
*Data not available for Swaziland.
60% 58% 59%
29% 34% 31%
11% 8% 10%
0%
50%
100%
Pre-ART ART Overall
Women 15+ Men 15+ Children <15
Cumulative enrollment in ICAP-supported HIV care and treatment programs by age and sex
as of September 2007
Source: ICAP URS, November 2007
n=164,491 n=136,252 N=300,743
% p
atie
nts
59%67% 66% 63% 62% 61% 60% 59%
1%
31%
29% 27%28% 31%
28% 29% 34%33%
1%
10%4% 7% 10% 8%
11% 11% 7% 10% 8%
98%
57%54%
37%
0%
50%
100%
Women 15+ Men 15+ Children <15
Cumulative HIV care enrollment in ICAP-supported HIV care and treatment programs by age, sex, and
country as of September 2007
Source: ICAP URS, November 2007
n=40,903n=29,169n=13,098 n=22, 010 n=19,869 n=96,816n=40,575 n=21,743 n=11,925n=300,743 n=4,635
% p
atie
nts
in H
IV c
are
58%65% 64% 63% 61% 60% 59% 59%
54%
1%
33%
31%28% 31% 32% 30% 30% 34%
37%
2%
9%5%
8% 6% 7% 10% 10%7% 9%
6%
96%
53%
42%
0%
50%
100%
Women 15+ Men 15+ Children <15
Cumulative ART enrollment in ICAP-supported HIV care and treatment programs by age, sex, and country
as of September 2007
Source: ICAP URS, November 2007
n=1,938n=14,161n=23,060 n=7,700 n=9,589 n=30,490n=5,795 n=8,721 n=11,925n=136,252 n=22,873
% p
atie
nts
on A
RT
60%
49% 46%
24% 23%16%
5%
17%
20% 27%
29%
25%
22%23%
48%
35%36%
18%
26%
22%
27%25%
29%
58%54%
31%38%35%
52%49%
0%
50%
100%
0-1 year 2-4 years 5-14 years Unknown
Cumulative pediatric HIV care enrollment in ICAP-supported HIV care and treatment programs by age and
country as of September 2007* n=782 n=2,841n=1,255 n=1,513 n=3,460n=9,757n=4,564 n=2,432 n=3,220n=29,824
Source: ICAP URS, November 2007
*Data not available for Swaziland.
% p
edia
tric
pat
ient
s in
HIV
car
e
41%
30% 29%
18%11%
7%3%
34%
30%27%
28%
16%
24%
43%
50%
6% 7%
31%
8%
19% 20%
27%
28% 22%34%
24%
61%65%48% 58%
33%48%
69%
0%
50%
100%
0-1 year 2-4 years 5-14 years Unknown
Cumulative pediatric ART enrollment in ICAP-supported HIV care and treatment programs by age and country
as of September 2007* n=846 n=667n=2,720 n=1,850 n=1,296n=1,867n=348 n=375 n=1,442n=11,411
Source: ICAP URS, November 2007
*Data not available for Swaziland.
% p
edia
tric
pat
ient
s on
AR
T
4%13% 9% 7% 2% 2% 1%
8%
11%8% 9%
11% 7% 8%3%
13%
89%76%
84% 84% 87% 91% 91% 97%87%
0%
50%
100%
Overa
ll
Nigeria
South
Afri
ca
Tanza
nia
Kenya
Moz
ambi
que
Ethiop
ia
Rwanda
Leso
tho
% Eligible, but not started % Eligible, started % Not eligible
ART eligibility and initiation among patients receiving HIV care in ICAP-supported HIV care and treatment
programs during July-September 2007*
*Data not available for Swaziland and Zambia.
Source: ICAP URS, November 2007
% p
atie
nts
ART regimens distributed to adults in ICAP-supported HIV care and treatment programs
during July-September 2007*Overall
n=86,485
Ethiopia
n=15,058
Kenya
n=5,528
Lesotho
n=4,266
Mozambique
n=22,670
Nigeria
n=4,904
Rwanda
n=9,932
South Africa
n=17,098
Tanzania
n=7,029
1st line regimen
d4T-3TC-NVP
40,887
(50%)8,225 (55%)
4,743
(86%)2,688 (49%)
13,641
(60%)2,330 (48%)
4,487 (45%)
2,443
(14%)
5,018
(71%)
d4T-3TC-EFV
20,528
(25%)3,054 (20%)
595
(11%)
720
(13%)
1,383
(6%)
159
(3%)
783
(8%)
13,742
(80%)
812
(12%)
ZDV-3TC-NVP
9,119
(11%)2,309 (15%)
103
(2%)
580
(10%)
552
(2%)2,179 (44%)
3,147 (32%)
152
(1%)
677
(10%)
ZDV-3TC-EFV
3,496
(4%)
1,036
(7%)
41
(1%)
243
(4%)
35
(0.2%)
229
(5%)
1,097
(11%)
543
(3%)
515
(7%)
2nd line regimen
981
(1%)
376
(2%)
21
(0.4%)
32
(1%)
106
(0.5%)
7
(0.1%)
337
(3%)
127
(1%)
7
(0.1%)
Unknown regimen
7,208
(8%)
58
(0.4%)
25
(0.5%)
3
(0.1%)
6,953
(31%)
0
(0%)
81
(1%)
91
(1%)
0
(0%)
*Data not available for Swaziland and Zambia.
Source: ICAP URS, November 2007
Overalln=7,989
Ethiopian=1,032
Kenyan=639
Lesothon=252
Mozambiquen=2,368
Nigerian=300
Rwandan=1,161
South Africa*n=1,702
Tanzanian=535
1st line regimen
d4T-3TC-NVP 2,128(27%)
210(20%)
311 (49%)
142 (22%)
690 (29%)
17(6%)
514 (44%)
35(2%)
209(39%)
d4T-3TC-EFV 1,462(18%)
78(8%)
61 (10%)
18 (3%)
52 (2%)
15 (5%)
124 (11%)
1,096(64%)
18(3%)
ZDV-3TC-NVP 2,044(26%)
557 (54%)
196 (31%)
77 (12%)
394 (17%)
204 (68%)
323 (28%)
29(2%)
264(49%)
ZDV-3TC-EFV 639(8%)
91 (9%)
37(5%)
8 (1%)
13(1%)
64 (21%)
175 (15%)
207(12%)
44(8%)
Other** 272(3%)
0(0%)
0(0%)
0(0%)
0(0%)
0(0%)
0(0%)
272(16%)
0(0%)
2nd line regimen** 213(3%)
0(0%)
4 (1%)
0 (0%)
52(2%)
0 (0%)
20 (2%)
48(3%)
0(0%)
Unknown 1,231(15%)
89(9%)
30 (5%)
7(1%)
1,167 (49%)
0(0%)
5(0.4%)
15(1%)
0(0%)
ART regimens distributed to children in ICAP-supported HIV care and treatment programs during
July-September 2007*
* Data not available for Swaziland and Zambia.** In South Africa, d4T-3TC-LPV/r is also prescribed as a first-line regimen for pediatric patients.
Source: ICAP URS, November 2007
Completeness of CD4 count data at baseline and 6 months after ART initiation among multiple cohorts,
July-September 2007*
85%
97% 97% 95%88%
76% 74% 74%
60%
46%
75%
63%
51% 50% 47%
33%25% 25%
0%
50%
100%
Overa
ll
Rwanda
South
Afri
ca
Ethiop
ia
Leso
tho
Kenya
Moz
ambi
que
Nigeria
Tanza
nia
Baseline (6-mo cohort) 6-month
Source: ICAP URS, November 2007
*CD4 data available for a subset of ART patients, and data not available for Swaziland and Zambia.
% p
atie
nts
with
CD
4 co
unt
Completeness of CD4 count data at baseline and 12 months after ART initiation among multiple cohorts,
July-September 2007*
83%
99% 96% 93% 94%
58%
75%
86%
45%40%
51%46%
38% 38% 40% 43%
16% 18%
0%
50%
100%
Overa
ll
Rwanda
South
Afri
ca
Ethiop
ia
Leso
tho
Kenya
Moz
ambi
que
Nigeria
Tanza
nia
Baseline (12-mo cohort) 12-month
Source: ICAP URS, November 2007
*CD4 data available for a subset of ART patients, and data not available for Swaziland and Zambia.
% p
atie
nts
with
CD
4 co
unt
Weighted Average median CD4 count at baseline and 6 and 12 months after ART initiation among
multiple cohorts, July-September 2007*
135
202
153 143 129 122 118 111 109
311346
305331 326
288 303
241251264251283
304322326
277 286
339
0
250
500
CD
4 c
ell
cou
nt (
cells
/uL)
Baseline CD4 6-month CD4 12-month CD4
**CD4 data available for a subset of ART patients, and data not available for Swaziland and Zambia.
Source: ICAP URS, November 2007
Average median CD4 count (cells/µL) increase after 6 and12 months of ART in ICAP-supported care and
treatment programs by country, July-September 2007*
137
154 152 147136 134 134
124114
181
208
171
205221
182192
168
147
0
100
200
Me
dia
n in
cre
as
e in
CD
4 c
ell
co
un
t
6 months 12 months*CD4 data available for a subset of ART patients.
Source: ICAP URS, November 2007
Net proportion of patients discontinuing ART at ICAP-supported HIV care and treatment programs
as of September 2007*
Continued ART 117,157
86%
Discontinued 19,095
14%
*Excludes patients who transferred out and unknowns.
** Includes known deaths only.
Lost to follow-up 57%
Dead** 38%
Stopped ART 5%
Source: ICAP URS, November 2007
10.5 per 1,000 person-years
79 per 1,000 person-years
119 per 1,000 person-years
57%
82% 79%
57% 57% 54% 53% 48%
0%
38%
17% 20%
42% 41%36%
47%43%
75%
86%
5% 1% 1% 1% 2%10%
0%9% 11% 14%
0%
50%
100%
Lost to follow-up **Died Stopped ART
Reasons for ART discontinuation in ICAP-supported HIV care and treatment programs by
country as of September 2007*
•Excludes patients who transferred out.•** Includes known deaths only.
Source: ICAP URS, November 2007
% p
atie
nts
0
50,000
100,000
Oct 04 Jan 05 Apr 05 Jul 05 Oct 06 Jan 06 Apr 06 Jul 06 Oct 06 Jan 07 Apr 07 Jul 07
Cu
mu
lati
ve p
erso
n-y
ears
on
AR
T
0
100
200
300
Cu
mu
lati
ve e
ven
ts p
er 1
,000
per
son
-yea
rs
Cumulative Person-Years on ART Known deaths and lost to follow up Known deaths Lost to follow-up
Cumulative person-years on ART, rates of stopped ART, death, and lost to follow up at ICAP-supported care and treatment programs, October 2004 – September 2007
PMTCT services
Pregnant women counseled and tested inICAP-supported PMTCT programs,
by quarter, April-September 2007
0
25,000
50,000
Apr-Jun Jul-Sept
1st ANC Counseled Tested Seroprevalence ART prophylaxis
Source: ICAP URS, November 2007
Num
ber
of
wom
en
Pregnant women counseled and tested inICAP-supported PMTCT programs,
April-September 2007
0
15,000
30,000
Nigeria Mozambique Ethiopia Rwanda Tanzania
1st ANC Counseled Tested Seroprevalence ART prophylaxis
Source: ICAP URS, November 2007
Num
ber
of
wom
en
HIV-infected pregnant women receiving ART prophylaxis in ANC at ICAP-supported PMTCT
programs, April-September 2007
0%
50%
100%
Overall Ethiopia Tanzania Mozambique Nigeria Rwanda
sd-NVP AZT + sd-NVP HAART
n=157 n=235 n=1,112 n=829 n=339n=2,672
Source: ICAP URS, November 2007
Num
ber
of
wom
en
TB/HIV services
52%
91%
80%
57%54%
46%
33%27%
63%
24%20%
5% 5%
55%
22%26%
13%
39%
87%
9%
0%
50%
100%
Overall South Africa* Rwanda Nigeria Tanzania Kenya Mozambique
Screened Screened positive Diagnosed/Initiated TB treatment
Screening and treatment for active TB among HIV positive persons enrolled in ICAP-supported care and treatment
programs, by country January-September 2007
Source: ICAP URS, November 2007
% a
ll pa
tient
s
n=42,364 n=1,097 n=5,837 n=8,582 n=8,102 n=7,695 n=11,051
75%
98%
74%
67%
52%
23%
46%
13%
38%
63%
80%
72%
50%50%48%
36%
100%
0%
50%
100%
Overall Nigeria Ethiopia Mozambique South Africa Kenya
Tested HIV-positive Enrolled in care and treatment
HIV testing and linkages with care and treatment for TB patients enrolled in ICAP-supported TB treatment programs, by country January-September 2007
* Kenya did not report the number of new TB patients. The number represents the number who were tested.
Source: ICAP URS, November 2007
% a
ll pa
tient
s
New TB patients n=17,637 n=1,858 n=14,664 n=707 n=408 n=2,768*
41%
54% 52%
0%
50%
100%
Jan 07 Apr 07 Jul 07
Proportion of new HIV patients screened at enrollment over time in ICAP-supported care and treatment
programs, January 2007-September 2007
Source: ICAP URS, November 2007
76%
66%
75%
0%
50%
100%
Jan 07 Apr 07 Jul 07
Proportion of new TB patients tested for HIV over time in ICAP-supported TB treatment programs,
January 2007-September 2007
Source: ICAP URS, November 2007